These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 21646575)

  • 41. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.
    Erritzoe D; Rasmussen H; Kristiansen KT; Frokjaer VG; Haugbol S; Pinborg L; Baaré W; Svarer C; Madsen J; Lublin H; Knudsen GM; Glenthoj BY
    Neuropsychopharmacology; 2008 Sep; 33(10):2435-41. PubMed ID: 18288096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.
    Rasmussen H; Erritzoe D; Andersen R; Ebdrup BH; Aggernaes B; Oranje B; Kalbitzer J; Madsen J; Pinborg LH; Baaré W; Svarer C; Lublin H; Knudsen GM; Glenthoj B
    Arch Gen Psychiatry; 2010 Jan; 67(1):9-16. PubMed ID: 20048218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of brain SERT occupancy by resveratrol against MDMA-induced neurobiological and behavioral changes in rats: A 4-[¹⁸F]-ADAM/small-animal PET study.
    Shih JH; Ma KH; Chen CF; Cheng CY; Pao LH; Weng SJ; Huang YS; Shiue CY; Yeh MK; Li IH
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):92-104. PubMed ID: 26612383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function.
    Callaghan PD; Owens WA; Javors MA; Sanchez TA; Jones DJ; Irvine RJ; Daws LC
    J Neurochem; 2007 Feb; 100(3):617-27. PubMed ID: 17181558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroimaging of chronic MDMA ("ecstasy") effects: A meta-analysis.
    Müller F; Brändle R; Liechti ME; Borgwardt S
    Neurosci Biobehav Rev; 2019 Jan; 96():10-20. PubMed ID: 30439373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.
    Buchert R; Thomasius R; Petersen K; Wilke F; Obrocki J; Nebeling B; Wartberg L; Zapletalova P; Clausen M
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):188-99. PubMed ID: 16133393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic treatment with a serotonin(2) receptor (5-HT(2)R) agonist modulates the behavioral and cellular response to (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA].
    Ross JD; Herin DV; Frankel PS; Thomas ML; Cunningham KA
    Drug Alcohol Depend; 2006 Feb; 81(2):117-27. PubMed ID: 16054778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys.
    Banks ML; Czoty PW; Gage HD; Bounds MC; Garg PK; Garg S; Nader MA
    Neuropsychopharmacology; 2008 Jan; 33(2):219-25. PubMed ID: 17443127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines.
    Xie T; Tong L; McLane MW; Hatzidimitriou G; Yuan J; McCann U; Ricaurte G
    Neuropsychopharmacology; 2006 Dec; 31(12):2639-51. PubMed ID: 16452989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain.
    Zhang Y; Liu F; Xiao H; Yao X; Li G; Choi SR; Ploessl K; Zha Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Nov; 66():1-9. PubMed ID: 30096380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study.
    Marner L; Frokjaer VG; Kalbitzer J; Lehel S; Madsen K; Baaré WF; Knudsen GM; Hasselbalch SG
    Neurobiol Aging; 2012 Mar; 33(3):479-87. PubMed ID: 20510480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET.
    Li IH; Huang WS; Shiue CY; Huang YY; Liu RS; Chyueh SC; Hu SH; Liao MH; Shen LH; Liu JC; Ma KH
    Neuroimage; 2010 Jan; 49(2):1259-70. PubMed ID: 19682588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function.
    Curran HV; Verheyden SL
    Psychopharmacology (Berl); 2003 Aug; 169(1):91-103. PubMed ID: 12759801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brain serotonin synthesis in MDMA (ecstasy) polydrug users: an alpha-[(11) C]methyl-l-tryptophan study.
    Booij L; Soucy JP; Young SN; Regoli M; Gravel P; Diksic M; Leyton M; Pihl RO; Benkelfat C
    J Neurochem; 2014 Dec; 131(5):634-44. PubMed ID: 25041501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contractile effects of 3,4-methylenedioxymethamphetamine on the human internal mammary artery.
    Silva S; Carvalho F; Fernandes E; Antunes MJ; Cotrim MD
    Toxicol In Vitro; 2016 Aug; 34():187-193. PubMed ID: 27079619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.
    McCann UD; Szabo Z; Scheffel U; Dannals RF; Ricaurte GA
    Lancet; 1998 Oct; 352(9138):1433-7. PubMed ID: 9807990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings.
    Reneman L; Lavalaye J; Schmand B; de Wolff FA; van den Brink W; den Heeten GJ; Booij J
    Arch Gen Psychiatry; 2001 Oct; 58(10):901-6. PubMed ID: 11576026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
    Reneman L; Schilt T; de Win MM; Booij J; Schmand B; van den Brink W; Bakker O
    J Psychopharmacol; 2006 May; 20(3):389-99. PubMed ID: 16574713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases.
    Licht CL; Christoffersen M; Okholm M; Damgaard L; Fink-Jensen A; Knudsen GM; Erritzoe D
    Hum Psychopharmacol; 2012 Jul; 27(4):352-63. PubMed ID: 22696164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
    Meyer JS; Piper BJ; Vancollie VE
    Ann N Y Acad Sci; 2008 Oct; 1139():151-63. PubMed ID: 18991859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.